Latest Dilution News

Novonix has secured A$20.7 million from an institutional placement at a 33% discount, alongside a A$3 million Share Purchase Plan for existing shareholders, aiming to fund production capacity expansion amid growing battery demand.

Resources & Energy Group (ASX:REZ) has locked in a binding term sheet with Rembrandt Mining to kickstart gold production at its Maranoa deposit, preserving full ownership while shifting capital risk to Rembrandt and capturing enhanced profit shares at higher gold prices.

International Graphite Ltd (ASX:IG6) has partnered with Alkeemia S.p.A. to establish a graphite processing facility in Italy, aiming for first production in the second half of 2027 and a final investment decision by Q3 2026.

Critica Limited is progressing its Jupiter and Mt Lindsay projects with key resource updates, metallurgical breakthroughs, and strategic partnerships, targeting Scoping Study completion in Q3 2026.

Flight Centre Travel Group has trimmed its FY26 profit forecast due to Middle East conflict impacts on leisure travel, while launching a fresh $200 million share buy-back reflecting confidence in recovery.

Future Generation Global Limited (ASX:FGG) has updated its special dividend details for the six months ending December 2025, confirming a fully franked 3-cent payout and outlining its dividend reinvestment plan pricing.

Bounty Oil & Gas has finalised the first tranche of a $4 million share placement and converted $200,000 of debt into shares, bolstering its capital for drilling and development across Australian oil and gas projects.

ALS Limited has confirmed its ordinary dividend of AUD 0.231 per share for the six months ending March 2026, introducing multi-currency payment options and appointing Macquarie Securities to manage on-market share purchases for its Dividend Reinvestment Plan.

Racura Oncology has raised $34.3 million through shareholder-backed initiatives, securing funding for its lead asset RC220’s clinical trials in AML, EGFRm lung cancer, and cardioprotection in solid tumour patients.

Hydrix Limited has secured $5.22 million from its retail entitlement offer, leaving nearly $3 million in entitlements unsold, which will be offered separately under a shortfall offer managed by Peak Asset Management.

Spenda Limited has launched the retail component of its $8.545 million accelerated entitlement offer, aiming to recapitalise, reduce debt, and support product development. Eligible shareholders can subscribe for 7 new shares per existing share, with free attaching options exercisable until 2031.

TZ Limited (ASX:TZL) is raising $3.08 million through a $0.50 million placement and a $2.58 million entitlement offer at 3 cents per share to repay debt, fund acquisitions, and accelerate product development.